Suspension of trading

NeuBase Therapeutics, Inc. Stock Nasdaq

NBSE

US64132K2015

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 23:30:00 10/05/2024 +03			5-day change	1st Jan Change
0.3780 ^USD	-3.20%		-.--%	-

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.12M 1.05M 962K 1.8M 122M 1.84M 12.43M 4.86M 60.56M 4.8M 4.69M 209M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.12M 1.05M 962K 1.8M 122M 1.84M 12.43M 4.86M 60.56M 4.8M 4.69M 209M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news : NeuBase Therapeutics, Inc.

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
27/06/24	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
29/05/24	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	01/11/2021

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	04/01/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-3.20%	-.--%	-	-	1.39M
LONZA GROUP AG	+0.47%	+6.53%	+0.59%	+14.33%	48.95B
IQVIA HOLDINGS INC.	+1.90%	+24.70%	+27.25%	+9.47%	40.75B
REVOLUTION MEDICINES, INC.	-1.60%	-1.15%	+388.84%	+603.70%	38.46B
BEONE MEDICINES AG	-0.98%	+2.28%	+7.02%	+45.34%	36.38B
CELLTRION, INC.	+1.47%	+5.82%	+5.76%	+43.52%	28.45B
ASCENDIS PHARMA A/S	-0.94%	+0.05%	-	-	16.62B
MEDPACE HOLDINGS, INC.	+2.44%	+10.76%	+30.59%	+129.56%	16.33B
ICON PUBLIC LIMITED COMPANY	-1.14%	+6.52%	-3.80%	-29.33%	13.65B
EUROFINS SCIENTIFIC SE	+0.23%	+4.05%	+4.12%	+9.94%	13.56B
Average	-0.14%	+5.79%	+57.55%	+103.32%	28.13B
Weighted average by Cap.	+0.22%	+6.92%	+71.95%	+122.80%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company